CSL Behring is a global biotherapeutics leader driven by a promise to save lives. Focused on serving patients’ needs by using the latest technologies, CSL Behring discovers, develops and delivers innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. CSL Behring uses three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring’s parent company, CSL, headquartered in Melbourne, Australia, employs more than 30,000 people, and delivers its lifesaving therapies to people in more than 100 countries.
CSL Behring develops and delivers innovative medicines for treating bleeding disorders, immune deficiencies and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha 1 Antitrypsin Deficiency, among others.